P198  Efficacy and safety of secukinumab in ankylosing spondylitis: real-world data from Midlands Ankylosing Spondylitis Collaboration (MASC)

Conclusion This multi-centre retrospective analysis found secukinumab to be clinically effective in 68% of patients with AS. There was significant improvement in BASDAI, VAS and CRP levels at week16. Compared to anti-TNF resistant patients, TNF-Naïve responded better to secukinumab, although both showed go od clinical improvement. These findings support the use of secukinumab in the treatment of AS, as a first line therapy or for those who have failed anti-TNF therapy. Safety signals observed in the real-word data set were consistent with those seen in the clinical trials and the Summary of Product Ch aracteristics.Disclosure N. Jain: None.R. Laxminarayan: Honoraria; Honorarium from Novartis, Lilly, Pfizer and Abvie.A. Moorthy: Honoraria; Speaker and conference fee MSD, Novartis, Abbvie.R. Amarasena: None.N. Cleaton: None.G. Kakade: None.A. Gunawardane: None.T. Khan: None.H. Sapkota: None.N. Barkham: Grants/research support; research funding from Novartis, Eli Lilly, UCB.
Source: Rheumatology - Category: Rheumatology Source Type: research